New hope for advanced breast cancer: experimental drug takes on chemo
NCT ID NCT06343948
First seen Apr 17, 2026 · Last updated May 10, 2026 · Updated 6 times
Summary
This study tests a new drug called BL-B01D1 against standard chemotherapy for people with advanced HR+HER2- breast cancer that has stopped responding to previous treatments. About 383 adults will be randomly assigned to receive either the new drug or a doctor-chosen chemo. The goal is to see if BL-B01D1 can slow cancer growth better than current options.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HR+/HER2- BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
Conditions
Explore the condition pages connected to this study.